<DOC>
	<DOCNO>NCT02586636</DOCNO>
	<brief_summary>Metformin first-line treatment medical management Type 2 Diabetes . Up 25 % patient experience significant gastrointestinal symptom approximate 5 % , side-effects result discontinuation metformin . It would great clinical significance underlie cause intolerance identify . Recent data highlight metformin transporter gut - Organic Cation Transporter 1 ( OCT1 ) - potential culprit variability metformin tolerance . Across diabetic population , one four people show single reduce function allele OCT1 , approximately 8 % two reduced function allele . This may increase risk individual experience metformin-associated side-effects , potentially due accumulation within cell line intestine . The investigator aim show loss function OCT1 , either due genetic variation drug inhibition OCT1 , may lead increase symptom associate metformin intolerance . The study undertaken Clinical Research Centre Ninewells Hospital , Dundee . The investigator recruit participant GoDARTS study ( Genetics Diabetes Audit Research Tayside Study ) . The participant healthy control , i.e . non-diabetic , recruit accord genotype OCT1 ( information GoDARTS ) . The volunteer enter match cross-over study two treatment period . Metformin take treatment period alongside either Omeprazole ( proton pump inhibitor use prevent excess stomach acid , know interact OCT1 ) placebo . The metformin dose increase gradually period , maximum tolerate dose . The investigator expect see low maximum tolerate dose individual loss function genotype , take concurrent omeprazole compare placebo . The study last approximately 9 week . Volunteers 3 visit CRC , weekly phone call interview .</brief_summary>
	<brief_title>Impact OCT1 Metformin Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Aged 18 80 White European ( limit genetic variation much possible ) Nondiabetic No previous treatment metformin No known gastrointestinal pathology e.g . inflammatory bowel disease , IBS , coeliac No daily treatment PPI , antispasmodic , antimotility drug No daily OCT1 inhibiting drug Able complete symptom severity score Bristol stool chart independently i.e . cognitive impairment visual impairment Normal renal function eGFR &gt; 60 Known OCT1 genotype either normal ( `` wild type '' ) two reduce function allele . Does meet inclusion criterion Heterozygous OCT1 genotype i.e . one reduced function allele Recent involvement ( &lt; 30 day ) CTIMP Pregnancy plan conceive Inability/unwillingness comply protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Metformin</keyword>
	<keyword>OCT1</keyword>
</DOC>